The WHO's New Cancer Projections: What NPs Need to Know

 

NP CHRONICLES

Clinical Education for NP Students & New Graduates

The WHO's New Cancer Projections: What NPs Need to Know

Global Health  |  Oncology Prevention  |  Health Equity

A new World Health Organization report, released this month, offers a sobering long-range forecast: global cancer cases are projected to climb from roughly 20.6 million in 2024 to as many as 35 million a year by 2050 — a jump of about 67 percent. The report, covered by the Washington Post's Daniel Wu, is not primarily a story about medical failure. It's a story about demographics, risk factor exposure, and above all, deep inequity in who gets access to prevention, early detection, and treatment.

For nurse practitioners, this report lands close to home. Whether you're doing primary care screening, managing chronic disease risk factors, or counseling patients on tobacco and alcohol use, you are already working the levers this report identifies as most fixable. Here's what's in the WHO's findings and why it matters for day-to-day practice.

The Headline Numbers

Metric	2024	2050 (projected)
Global annual cancer cases	~20.6 million	~35 million
Global cancer deaths (2024)	9.7 million	—
Breast cancer 5-yr survival, high-income countries	~85–90%	—
Breast cancer 5-yr survival, low-income countries	<30%	—

 

The report projects that cancer incidence will rise in every region of the world, but unevenly — the steepest increases are expected in Africa and the Eastern Mediterranean region, areas with the least infrastructure to absorb that growth. By contrast, the rate of new cancer cases in the United States has been relatively stable in recent years, according to the National Institutes of Health, even as global numbers climb.

Why Cases Are Rising: It's Not Just “More Cancer”

The WHO report is careful to separate several distinct drivers, and the distinction matters for how we talk to patients and communities about it:

•     Aging populations. As life expectancy rises worldwide, more people live long enough to develop cancers that are fundamentally diseases of accumulated cellular damage and age.

•     Known, modifiable risk factors — principally tobacco, alcohol use, and rising obesity rates. These are the factors the report repeatedly flags as both a major driver of the projected increase and the most addressable lever available.

•     Improved surveillance and diagnostic capacity, which sounds paradoxical but is genuinely part of the story: better screening and imaging catch cancers that would previously have gone undiagnosed or been attributed to another cause of death.

Emil Lou, MD, an oncologist at the University of Minnesota quoted in the Post's coverage, framed the tension well: treatments like immunotherapy have measurably improved survivability for many patients, but the rising global case count is a reminder that better treatment alone doesn't solve a prevention and access problem.

The Equity Gap Is the Real Story

The single most striking figure in the report is the gap in outcomes by income level. In high-income countries, five-year net survival for breast and prostate cancer sits around 80 to 90 percent. In low-income countries, breast cancer survival drops below 30 percent — not because the biology of the disease is different, but because access to timely diagnosis and treatment is.

Cervical cancer tells a similarly stark story in the other direction. Isabelle Soerjomataram, an epidemiologist with the International Agency for Research on Cancer, noted that cervical cancer has been pushed to “almost elimination” in parts of Europe and North America, driven largely by HPV vaccination and screening infrastructure — while it remains the leading cancer diagnosis in much of sub-Saharan Africa.

CLINICAL BOTTOM LINE The WHO projects a 67% rise in global cancer incidence by 2050, driven mainly by aging populations and modifiable risk factors — tobacco, alcohol, and especially obesity. Survival gaps between high- and low-income countries remain enormous (breast cancer 5-year survival: >85% vs. <30%), underscoring that access to prevention and early detection, not just treatment innovation, determines outcomes. An estimated 4 in 10 cancer cases worldwide are linked to risk factors we already know how to address.

Where the Report Sees Progress — and Where It Doesn't

Encouraging trends

•     Global tobacco use has dropped 27 percent since 2010, a meaningful public health win the report explicitly credits.

•     HPV vaccination has expanded significantly: 85 percent of countries now include the HPV vaccine in national immunization programs, and an estimated 31 percent of girls globally have received their first dose, up from 17 percent in 2019.

The stalled trend: obesity

The report's most alarming finding may be the near-universal failure to curb rising obesity rates. Obesity is linked to more than a dozen cancers, including liver, pancreatic, and colorectal cancer. WHO cancer control lead André Ilbawi was blunt about the trajectory: obesity-associated cancers are on track to become the norm in a significant number of countries within the next two to three decades.

NUANCE TO FLAG It's tempting to read a 67% projected increase in cases as purely bad news, but the report's authors are explicit that rising case counts partly reflect success — aging populations are, in large part, a product of improved life expectancy and reduced deaths from other causes earlier in life. The real alarm in this report isn't that people are living long enough to get cancer; it's that so much of the projected increase is preventable and that survival outcomes remain so unevenly distributed by income. Framing this accurately matters when discussing the report with patients, who may otherwise hear only “cancer is getting worse” without the context of what's actually driving it.

What This Means for Your Practice

Four in 10 new cancer cases worldwide are linked to risk factors we already know how to address, according to Soerjomataram. For NPs in primary care, that statistic is essentially a job description. The interventions with the clearest evidence of impact at the population level are ones most NPs are already positioned to deliver at the individual level:

•     Tobacco cessation counseling and pharmacotherapy at every applicable visit, not just annual wellness exams.

•     HPV vaccination counseling and catch-up dosing for eligible patients and their children — particularly relevant given how much of the global cervical cancer gap traces back to vaccination access.

•     Alcohol use screening using a validated tool (AUDIT-C or similar) integrated into routine visits, not reserved for patients who volunteer a concern.

•     Weight management conversations framed around cancer risk specifically — many patients are unaware that obesity is linked to liver, pancreatic, and colorectal cancers, and hearing that connection directly from a clinician can shift motivation.

•     Appropriate screening referrals (breast, cervical, colorectal) without assuming access barriers that may not apply to your specific patient — and proactively addressing the ones that do, such as cost, transportation, or health literacy.

Global Numbers, Local Relevance

It's easy to read a WHO global report and file it under “not my patient population.” But the same risk factors driving the global projection — tobacco, alcohol, obesity, and inconsistent access to screening — are exactly the factors that predict outcome disparities within the U.S. as well, across income levels, rural versus urban geography, and insurance status. The global report is, in a real sense, a magnified version of disparities many NPs already see in their own patient panels.

The encouraging half of this report is worth holding onto: unlike many of medicine's hardest problems, the biggest driver of preventable cancer burden identified here isn't a scientific unknown. It's an access and behavior-change problem — the kind NPs address in exam rooms every day.

 

Reference

Wu, D. (2026, July 8). Cancer cases worldwide are expected to soar in the coming decades, a report finds. Here's why. The Washington Post.